Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01716481
Other study ID # 2011-10-047
Secondary ID
Status Recruiting
Phase Phase 3
First received October 25, 2012
Last updated April 24, 2017
Start date November 2012
Est. completion date December 2017

Study information

Verified date April 2017
Source Samsung Medical Center
Contact Oh Young Bang, MD
Phone 82-10-3410-3599
Email nmboy@unitel.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.


Description:

In this study, we will use autologous 'ischemic' serum that obtained at the earliest time point as possible (immediate after randomization) for the purpose of ischemic preconditioning. We have recently conducted preclinical studies on the effects of ischemic preconditioning on the MSC functions. We have evaluated the characteristics of rat MSCs after culture with fetal bovine serum (FBS) or serum obtained from rat stroke model. Compared to FBS, the use of serum obtained from rat stroke model resulted in more rapid expansion of MSCs, which reduces cell preparation time by increase in G2/M phase, decreased cell death/senescence, increased trophic factor secretion, and increased migration capacity.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria:

1. Men or women (women must be of non-child bearing potential), age 30-75 yrs.

2. Have a stroke that is observed within 90 days of the onset of symptoms

3. Radiologically

1. Relevant lesions within the middle cerebral artery territory (MCA) as assessed using diffusion-weighted imaging (DWI).

2. The maximum diameter of the stroke region in any dimension must be =15 mm.

3. Not involving more than a half of the ipsilateral periventricular zone

4. Clinically (National Institutes of Health stroke scale, NIHSS)

1. Moderate-to severe persistent neurologic deficit (NIHSS of 6-21 inclusive)

2. New onset of extremity paresis on the affected side, defined as a score of 2-4 on the NIHSS Motor Arm (item 5) or Leg (item 6) question.

3. Must be alert or drowsy but easily arousable as defined by score of 0-1 on the NIHSS Level of Consciousness question (item 1).

4. "Slow recovery" defined as Change in NIHSS =1 point/3 days

5. Willingness

1. Reasonable likelihood of receiving standard physical, occupational and speech rehabilitation therapy as indicated for the post stroke deficits.

2. Able to participate in the evaluation process to the point of accurate assessment.

3. Willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures.

4. Evidence of a personally signed and dated informed consent document.

Exclusion Criteria:

1. Presence of significant disability prior to the current stroke. Significant disability is defined as having a pre-stroke modified Rankin score of 2 or more.

2. Have a stroke that is either

1. lacunar infarction

2. Hematologic cause of stroke

3. Recurrent or progressive stroke within 1 week at the time of screening.

3. Hematologic disorders or bone marrow suppression.

4. Have a severe medical illness

1. Severe heart failure

2. Severe febrile illness

3. Hepatic or renal dysfunction

4. Active cancer

5. Any evidence of chronic co-morbid condition or unstable acute systemic illnesses which, in the opinion of the investigator, could shorten the subject's survival or limit ability to complete the study.

5. Presence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis on admission blood tests

6. Presence of depression that is active and not adequately controlled such that it interfere with major activities of daily living immediately prior to the current stroke.

7. Presence of dementia prior to the current stroke that is likely to confound clinical evaluation.

8. Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test or lactating females.

9. Subjects considered unwilling or unable to comply with the procedures and study visit schedule outlined in the protocol

10. Subjects unwilling to undergo bone marrow aspiration

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Mesenchymal stem cell
intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum

Locations

Country Name City State
Korea, Republic of Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul

Sponsors (2)

Lead Sponsor Collaborator
Samsung Medical Center Pharmicell Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploration of biomarkers SDF(stromal cell-derived factor)-1? (chemokine) S100ß (protection and regeneration) HIF(Hypoxia-inducible factor)-1 (preconditioning) Circulating MSCs and MSC-derived microparticles (CD105-CXCR4(C-X-C chemokine receptor type 4)-PS(phosphoserine)) BDNF (Brain-derived neurotrophic factor) levels and it's polymorphism, and VEGF (Vascular endothelial growth factor) levels
Resting-state functional MRI & Diffusion tensor imaging
During 90 days after the cell treatment
Primary Categorical shift in modified Rankin scale (mRS) Categorical shift in mRS at 90 days after the cell treatment 90 days after the cell treatment
Secondary Change of National Institutes of Health stroke scale (NIHSS) Change of NIHSS between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Early improvement of National Institutes of Health stroke scale (NIHSS) =5 points improvement or score of 0-2 on NIHSS score at 14 days after treatment 14 days after the cell treatment
Secondary Dichotomized modified Rankin scale (mRS) mRS =2 at 90 days after treatment 90 days after the cell treatment
Secondary Change of modified Rankin scale (mRS) Change of mRS between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Dichotomized modified Barthel index (mBI) mBI =60 at 90 days after treatment 90 days after the cell treatment
Secondary Change of modified Barthel index (mBI) Change of mBI between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Change of gross motor function Change of Gross motor function (Motricity index and Fugl-Meyer assessment)between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Change of Fine motor function Change of Fine motor function (Purdue Pegboard test and Box and block test) between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Change of Mobility Change of Mobility (Functional ambulatory category and 10m-Gait speed) between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Change of mini-mental status exam (MMSE) Change of MMSE between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Change of quality of life Change of EuroQol 5d (EQ-5D) between pre- and post-treatment 90 days 90 days after the cell treatment
Secondary Safety outcome Death: All causes of death
Recurrence: Recurrent stroke or transient ischemic attack
The immediate reaction:
Allergic reactions (tachycardia, fever, skin eruption, leukocytosis) Local complications (hematoma or local infection at the site of bone marrow aspiration) Vascular obstruction (tachypnea, oliguria, or peripheral vascular insufficiency) Systemic complications (infections,laboratory findings).
Long-term adverse effects possibly related to MSC treatment Tumor formation (physical examination, plain x-ray, f/u MRI at 90 days after treatment), Aberrant connections (newly diagnosed seizure or arrhythmia)
During 90 days after the cell treatment
See also
  Status Clinical Trial Phase
Recruiting NCT03993236 - Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke Phase 4
Completed NCT04069767 - Innovative Physiotherapy in Stroke Rehabilitation N/A
Recruiting NCT06342206 - The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Enrolling by invitation NCT04956211 - Periodontal Treatment and Ischemic Stroke N/A
Active, not recruiting NCT05098236 - Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage N/A
Completed NCT03942588 - High-intensity Interval Training After Stroke N/A
Recruiting NCT04949334 - Effects of Respiratory Muscle Training in Patients With Acute Ischemic Stroke N/A
Terminated NCT04095767 - Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke N/A
Not yet recruiting NCT06352086 - Understanding Visual Processing After Occipital Stroke
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Completed NCT01937182 - The Efficacy of Citalopram Treatment in Acute Stroke Phase 2
Completed NCT03649295 - Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke N/A
Recruiting NCT05303649 - Effects of Neuronavigated Theta Burst Stimulation in Therapy of Post-stroke Aphasia N/A
Completed NCT04233515 - Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County
Completed NCT05102877 - Sensory Versus Motor Level Neuromuscular Electrical Stimulation N/A
Completed NCT04089917 - A Study of the Use of the Q Aspiration Catheter to Remove Clot in Stroke Patients
Completed NCT05221112 - Effects of PNF Patterns Training on Trunk Balance, and Gait in Chronic Stroke Patients N/A
Not yet recruiting NCT05035953 - Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke Phase 2
Completed NCT06326801 - Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients N/A